Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance

Ferreira, Magda; Ogren, Maria; Dias, Joana; Silva, Marta; Gil, Solange; Tavares, Luís; Aires-da-Silva, Frederico; Gaspar, Maria Manuela; Aguiar, Sandra I.

doi:10.3390/molecules26072047

Cited by 110 publications

(74 citation statements)

References 115 publications

(181 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also provide targeted delivery and controlled release of drugs. A positively charged liposome would target a negatively charged bacterial cell wall through electrostatic interactions [60,61]. The physicochemical properties would help in the accumulation of drugs at infected sites and direct interaction with bacteria [39].…”

Section: Discussionmentioning

confidence: 99%

Bacteriophage-Liposomes Complex, a Bi-therapy System to Target Streptococcus pneumonia and Biofilm: A Research Protocol

et al. 2021

View full text Add to dashboard Cite

Introduction: Streptococcus pneumoniae is a gram-positive bacterium, which is the leading cause of death for young children, elderly population, and immunocompromised patients. Its ability to mutate and become resistant to some of the strongest antibiotics makes them difficult to treat and increases the risk of disease spread. Although the development of stronger antibiotics to treat such microbes may be an option, they potentially pose a dangerous threat to the body. As such, a viable treatment option to fight against antimicrobial resistance has yet been found. Methods:The study focuses on utilizing a bi-therapy system to target S. pneumoniae in biofilm, which is the site of emerging antibiotic resistant mutants, by creating levofloxacin-liposomes carrying phages and testing them both in vitro and in vivo. Anticipated results: Using bacteriophage therapy and applying bacteriophage-antibiotic synergy, it is hoped to augment the potency of the treatment while lowering its side-effects. The Cp-1 bacteriophage-liposomes complexes are expected to be specific to the S. pneumoniae to carry antibiotics to sites of infection. Discussion: The therapy could ensure targeted bacterial lysis and site-directed delivery of low-dose drugs to decrease the toxicity effect of the antibiotics. Once the efficacy is established and is proven to be significant, its potency can be tested in BALB/cByJ mice models before bringing this therapy to animal trials then human clinical trials. Conclusion: Bacteriophages are very attractive therapeutic agents that effectively target pathogenic bacteria, safe for the human body, and highly modifiable to combat newly emerging bacterial threats. In addition to its many benefits, the use of bacteriophages could significantly reduce healthcare costs. The potential use of bacteriophages-liposomes complexes could be translated to treat respiratory infections in humans after confirming its efficacy in vitro and in vivo studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Bacteriophage-Liposomes Complex, a Bi-therapy System to Target Streptococcus pneumonia and Biofilm: A Research Protocol

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Nanoparticles including metallic nanoparticles, liposomes, and dendrimers appeared in response to the lack of antibiotics efficacy and drug resistance. These nanomaterials are very versatile, showing, for instance, the ability for encapsulation of antibiotics [ 114 , 115 ] and other antimicrobial agents. For example, it was recently demonstrated that the encapsulation of an antimicrobial glycolipid biosurfactant with the use of chitosan-based nanoparticles was effective against Helicobacter pylori biofilm [ 116 ].…”

Section: Antibacterial and Antibiofilm Strategiesmentioning

confidence: 99%

“…When the use of nanoparticles (NPs) as effective antimicrobial agents is considered, some key properties are also taken into account, such as their large surface area relative to a small size volume and their excellent predisposition for surface modifications. The development of nanotechnology for antimicrobial propose is widely investigated at the pre-clinical level, and some nanoparticles are already approved by the FDA for clinical use (as in the case of liposomal formulations and lipid-based vaccines) or are in clinical trials [ 114 ].…”

Section: Antibacterial and Antibiofilm Strategiesmentioning

confidence: 99%

The Two Weapons against Bacterial Biofilms: Detection and Treatment

et al. 2021

View full text Add to dashboard Cite

Bacterial biofilms are defined as complex aggregates of bacteria that grow attached to surfaces or are associated with interfaces. Bacteria within biofilms are embedded in a self-produced extracellular matrix made of polysaccharides, nucleic acids, and proteins. It is recognized that bacterial biofilms are responsible for the majority of microbial infections that occur in the human body, and that biofilm-related infections are extremely difficult to treat. This is related with the fact that microbial cells in biofilms exhibit increased resistance levels to antibiotics in comparison with planktonic (free-floating) cells. In the last years, the introduction into the market of novel compounds that can overcome the resistance to antimicrobial agents associated with biofilm infection has slowed down. If this situation is not altered, millions of lives are at risk, and this will also strongly affect the world economy. As such, research into the identification and eradication of biofilms is important for the future of human health. In this sense, this article provides an overview of techniques developed to detect and imaging biofilms as well as recent strategies that can be applied to treat biofilms during the several biofilm formation steps.

show abstract

“…A promising alternative to the search of new therapies are nanoantibiotics, the combination of approved antibiotics with the use of nanotechnology. Recent advances in this domain have enabled the development of drug delivery systems with improved pharmacokinetic characteristics and antimicrobial features [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin—Characterization and Biocompatibility in Mice

et al. 2021

View full text Add to dashboard Cite

Nanoantibiotics have proved improved pharmacokinetic characteristics and antimicrobial features. Recent studies have shown non-toxicity, non-immunogenicity, antioxidant, anti-hyperlipidemic, and hepatocyte protective actions, among other advantages of chitosan-based nanoparticles. The purpose of our study was the structural analysis of novel chitosan-coated vesicles entrapping erythromycin (ERT) and the assessment of their biocompatibility in mice. According to the group in which they were randomly assigned, the mice were treated orally with one of the following: distilled water; chitosan; ERT; chitosan vesicles containing ERT. Original nanosystems entrapping ERT in liposomes stabilized with chitosan were designed. Their oral administration did not produce sizeable modifications in the percentages of the leukocyte formula elements, of some blood constants useful for evaluating the hepatic and renal function, respectively, and of some markers of oxidative stress and immune system activity, which suggests a good biocompatibility in mice. The histological examination did not reveal significant alterations of liver and kidney architecture in mice treated with chitosan liposomes entrapping ERT. The results indicate the designed liposomes are a promising approach to overcome disadvantages of conventional ERT treatments and to amplify their benefits and can be further studied as carrier systems.

show abstract

Liposomes as Antibiotic Delivery Systems: A Promising Nanotechnological Strategy against Antimicrobial Resistance

Cited by 110 publications

References 115 publications

Bacteriophage-Liposomes Complex, a Bi-therapy System to Target Streptococcus pneumonia and Biofilm: A Research Protocol

Bacteriophage-Liposomes Complex, a Bi-therapy System to Target Streptococcus pneumonia and Biofilm: A Research Protocol

The Two Weapons against Bacterial Biofilms: Detection and Treatment

The Analysis of Chitosan-Coated Nanovesicles Containing Erythromycin—Characterization and Biocompatibility in Mice

Contact Info

Product

Resources

About